Post archive for ‘Company Reports’
Cadence: Product Recall Doesn’t Alter Sales Projections (CADX, $4.19)
I was somewhat alarmed to see a press release entitled “Cadence Pharmaceuticals Announces Voluntary Recall of One Lot of OFIRMEV® (Acetaminophen) Injection”. Cadence (CADX) is one of the stocks that I am recommending and my experience is that quality control issues can be very messy and disruptive. I wanted to follow-up with management to try […]
Vibex MTX is the Most Exciting Component of the Antares Investment Outlook (AIS, $2.74)
Investment Thesis I initiated coverage of Antares (AIS) on December 8, 2011 with a buy rating. Important factors driving my recommendation were its broad based relationship with Teva for developing injectable pharmaceuticals and the recently approved Anturol, a gel based product for urinary incontinence. I also felt that LibiGel could be a meaningful, but not […]
John Johnson Resigns as CEO, After Thinking It Over, I Continue with My Buy Recommendation (SVNT, $2.27)
The decision of John Johnson to go to Dendreon as CEO and Chairman after only one year at the helm as CEO of Savient can only be looked at as a negative. The question is whether this is enough of a negative for me to change my Buy opinion that started when I initiated coverage […]
Dendreon Turns Reins Over to New CEO (DNDN, $14.18)
Key Points Dendreon has made a sweeping change in management by bringing in John Johnson, who was serving as a board member, to be the new President, CEO and Chairman-elect of the Board of Directors. He immediately replaces Mitchell Gold as CEO and Richard Brewer has stepped down as Chairman of the Board. Mr. Gold […]
Quarterly Sales Show That Both Provenge and Zytiga Are Doing Very Well (DNDN, $13.58)
Investment Conclusion Both Zytiga and Provenge have had very successful launches in the US. Fears that Zytiga would negatively impact sales of Provenge are not borne out by the quarterly sales trends reported so far for the products. Provenge in 4Q, 2011 reported an upside sales surprise at the same time that Zytiga reported very […]
The Promise of the Antares Pipeline is the Basis of my Buy Recommendation (AIS, $2.40)
Investment Opinion The failure of the Libi-Gel trial rocked the stock of Antares (AIS) and caused it to drop from around $2.62 to $1.67 with a subsequent recovery to $2.40. I think that this reaction failed to recognize the broad potential of the Antares product line beyond Libi-Gel. In particular, I think that the market […]
Expanding on Clinical Trials of CPP-109 in Cocaine Addiction and Pre-Clinical Studies of CPP-115 (CPRX, $1.14)
Purpose of Report I recently initiated coverage of Catalyst Pharmaceutical Partners (CPRX). This report is a follow-on to that report which focuses on the clinical trials that have been conducted to date with CPP-109 (vigabatrin) in cocaine addiction. This provides perspective on the all-important ongoing US phase IIb trial. The company hopes to duplicate the […]
Many Investors Rate Ofirmev Launch a Failure-Not So Fast (CADX, $4.06)
Investment Opinion Many or most investors have written off the launch of Ofirmev as either disappointing or an outright failure. I think they are wrong. In its most recent company presentation, Cadence released some unusually detailed figures on the number of Ofirmev vials sold in each month of 2011. These show impressive sequential month over […]
Now That Pharmasset and Achillion Have Received Takeover Bids; Is Achillion Next? (ACHN, $9.72)
Following the announcement that Gilead was proposing to acquire Pharmasset (VRUS), I postulated in a note written on November 11, 2011 that Inhibitex (INHX) and Achillion (ACHN) were the next possible targets as big pharma companies seek to put together HCV drug assets. On January 13, Bristol-Myers announced that it proposed to acquire Inhibitex. I […]
Investors’ Concern About Launch of Intermezzo Weighs on the Stock and Creates a Buying Opportunity (TSPT, $8.21)
Investment View I believe that Transcept’s (TSPT) Intermezzo is an important new drug for insomnia and will be a commercial success. I am anticipating that Transcept’s marketing partner Purdue Pharmaceuticals will launch the product in mid-2012. There was a time when new product approvals and launches produced investor exuberance. Now they seem to be met […]